drugset / Trial / NCT00873730

Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain

NCT00873730

Phase 4 Completed 108 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to evaluate efficacy and safety of etanercept 100 mg (50 mg twice a week) compared with 50 mg once a week in adult subjects with ankylosing spondylitis (AS) and previous failure to usual practice therapies in Spain.

Timeline

Start
2006-12
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg